Enter inventor name

EPO Patents = 1

Average Co-Inventor Count = 5.0

ph-index = 7

Forward Citations = 159(Granted Patents)

Location History:

Toronto, CA (2003 - 2012)
Brampton, CA (2014 - 2016)

Company Filing History:

Pivotal Therapeutics, Inc.

patents

3 out of 3

Artemis Proteomics, Ltd.

Years Active: 2003-2016

Loading Chart...

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9248138 - Process and composition for stabilization of vulnerable plaque utilizing a combination of a statin and omega 3 fatty acids (2016-02-02),

2. 9119826 - Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels (2015-09-01),

3. 8952000 - Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events (2015-02-10),

4. 8951514 - Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels (2015-02-10),

5. 8715648 - Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics (2014-05-06),

6. 8263351 - Diagnostic methods for congestive heart failure (2012-09-11),

7. 7314717 - Biopolymer marker indicative of disease state having a molecular weight of 1562 daltons (2008-01-01),

8. 7294688 - Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons (2007-11-13),

9. 7229638 - Biopolymer marker indicative of disease state having a molecular weight of 1525 Daltons (2007-06-12),

10. 7125726 - Method and kit for diagnosing myocardial infarction (2006-10-24),

11. 7087435 - Biopolymer marker indicative of disease state having a molecular weight of 2753 daltons (2006-08-08),

12. 7049397 - Biopolymer marker indicative of disease state having a molecular weight of 1211 daltons (2006-05-23),

13. 7008800 - Biopolymer marker indicative of disease state having a molecular weight of 1077 daltons (2006-03-07),

14. 6998243 - Biopolymer marker indicative of disease state having a molecular weight of 1793 daltons (2006-02-14),

15. 6890763 - Biopolymer marker indicative of disease state having a molecular weight of 1350 daltons (2005-05-10),

Title: **Jason Yantha: Innovator in Cardiovascular Therapeutics**

Introduction

Jason Yantha, based in Toronto, Canada, is a prolific inventor with 27 patents to his name. His contributions primarily focus on developments in cardiovascular health, showcasing a commitment to enhancing patient care through innovative solutions.

Latest Patents

Among his latest patents, Yantha has made significant strides with two groundbreaking inventions. The first patent details a process and composition for stabilizing vulnerable plaque using a combination of statins and omega-3 fatty acids. This innovative treatment method targets individuals with omega-3 deficiencies while effectively managing cholesterol levels. The formulation consists of a high concentration of essential omega-3 fatty acids—including Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA), and Docosahexaenoic acid (DHA)—which work together to stabilize vulnerable plaque in cardiovascular patients.

His second patent involves a diagnostic assay and prescription medical food kit for the dietary management of patients with cardiovascular disease. This kit assists in evaluating and addressing deficiencies of blood EPA and DHA levels, providing a comprehensive approach to treatment. The formulation and diagnostic tool aim to improve cardiovascular health outcomes significantly.

Career Highlights

Yantha has collaborated with notable companies in the pharmaceutical industry, including Syn X Pharma, Inc. and Pivotal Therapeutics, Inc. His involvement with these companies has allowed him to develop cutting-edge therapies that address critical health issues.

Collaborations

Throughout his career, Jason has worked alongside esteemed colleagues such as George Jackowski and Brad Thatcher. These collaborations have contributed to the development of patented technologies that continue to impact the field of cardiovascular therapeutics positively.

Conclusion

Jason Yantha serves as a prime example of how innovation in the medical field can lead to remarkable advancements in patient care. His work on stabilizing vulnerable plaque and managing omega-3 deficiencies underscores the vital role of inventors in creating effective health solutions. The patents he has secured not only highlight his genius but also pave the way for future research and discovery in cardiovascular health management.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com